title: Low-temperature micronization of a peptide drug in fluid propellant: case study cetrorelix.
abstract: Aim of this study was to elaborate an efficient method for the micronization of the decapeptide cetrorelix (a GnRH-antagonist), in order to obtain a microsuspension as basis for other pharmaceutical preparations, such as e.g. inhalation aerosols. A modified pearl-mill coupled with a cryostat was used for the micronization of cetrorelix in fluid propellant and operated under different conditions. The obtained cetrorelix suspensions were analyzed for particle size distribution, purity of cetrorelix, and for metal contamination through abrasion from parts of the mill. The method allowed an effective micronization of cetrorelix. The mean particle size of the initial cetrorelix lyophilizate bulk ware was reduced from 52.5 microm (Volume Mean Diameter, VMD) down to 14.9, 6.1 and 3.1 microm, respectively, respectively. The HPLC analysis of all cetrorelix suspensions after micronization did not show signs of decomposition as compared to the initial product. The elementary analysis of the suspensions performed by inductively coupled plasma mass spectrometry revealed a negligible amount of contaminants in the suspension (Zr = max. 0.6 ppm; Fe, Cr, Ni, Ba, below limit of quantification, i.e. < 0.14 ppm). The only appreciable contaminant, Aluminum (Al = 1.1 ppm), was derived from the mechanical capping of aluminum canisters prior to analysis. The Zr determination in the suspension of 0.6 ppm, is still considered to be negligible as compared to the legally tolerated limit of air contamination. By low-temperature micronization in fluid propellant, fine drug suspensions of cetrorelix for pMDIs can be directly manufactured in one-step procedure without destruction of the peptide structure and without appreciable product contamination.
authors.affiliation: Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, 66123 Saarbrücken, Germany. rosario_lizio@roehm.com
authors.forename: R
authors.initials: R
authors.lastname: Lizio
authors.forename: M
authors.initials: M
authors.lastname: Damm
authors.forename: A W
authors.initials: AW
authors.lastname: Sarlikiotis
authors.forename: H H
authors.initials: HH
authors.lastname: Bauer
authors.forename: C M
authors.initials: CM
authors.lastname: Lehr
mesh_terms: D000280:Administration, Inhalation; D000335:Aerosol Propellants; D005615:Freezing; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D006727:Hormone Antagonists / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D006845:Hydrocarbons, Fluorinated; D008670:Metals / Q000032:analysis; D010316:Particle Size; D013535:Suspensions / Q000737:chemistry; D005466:Fluorocarbons
chemical_list: D000335:Aerosol Propellants; D007987:Gonadotropin-Releasing Hormone; D006727:Hormone Antagonists; D006845:Hydrocarbons, Fluorinated; D008670:Metals; D013535:Suspensions; C062876:cetrorelix; C094049:apaflurane; D005466:Fluorocarbons